Open Recruiting Phase 2 Trials for Anlotinib (DB11885)

IndicationStatusPhase
DBCOND0119362 (Open)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03936452Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell LymphomaTreatment